title: [Short-term effects of intravitreal injection of bevacizumab on macular edema due to central retinal vein occlusion].
abstract: OBJECTIVE
  To examine the short-term effects of intravitreal injections of bevacizumab on macular edema due to central retinal vein occlusion (CRVO).
  
  
  METHODS
  Twenty one eyes of 21 consecutive patients with macular edema due to CRVO were included. The patients received intravitreal injections of 1.25 mg bevacizumab at the initial examination. They were followed up with best-corrected visual acuity (BVCA), fluorescein angiography, and central macular thickness (CMT) by optical coherence tomography for more than 4 months. Whenever the macular edema recurred, another intravitreal bevacizumab was given.
  
  
  RESULTS
  The mean age of the patients was 68.1 +/- 11.8 and the mean follow up was 6.5 +/- 2.6 months. The mean baseline BVCA (logMAR) and CMT were 0.79 +/- 0.45 and 699 +/- 194 microm, respectively. After treatment, the mean BVCA improved significantly at 1 week (0.52 +/- 0.46, p<0.001), 1 month (0.48 +/- 0.46, p<0.001), 2 months(0.56 +/- 0.43, p<0.02), and 4 months (0.51 +/- 0.47, p<0.001). The mean CMT also decreased significantly at 1 week (296 +/- 86 microm, p<0.001), 1 month (286 +/-132 microm, p<0.001), 2 months (464 +/- 249 microm, p<0.05) and 4 months (362 +/- 198 microm, p<0.001). Similar effects on reducing CMT were obtained both after the initial injection and the second injection of bevacizumab.
  
  
  CONCLUSIONS
  Intravitreal injection of bevacizumab improved visual acuity and macular edema due to CRVO.
authors.affiliation: Department of Ophthalmology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan. ganka@med.u-toyama.ac.jp
authors.forename: Atsushi
authors.initials: A
authors.lastname: Hayashi
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Ueta
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Yunoki
authors.forename: Keiichi
authors.initials: K
authors.lastname: Mitarai
authors.forename: Akio
authors.initials: A
authors.lastname: Miyakoshi
authors.forename: Sachiko
authors.initials: S
authors.lastname: Takeda
authors.forename: Kazuya
authors.initials: K
authors.lastname: Fujita
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Watanabe
authors.forename: Shuichiro
authors.initials: S
authors.lastname: Yanagisawa
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Kitagawa
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012170:Retinal Vein Occlusion / Q000150:complications*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab